Published: 9 January 2019
Author(s): Marco Marietta, Federico Banchelli, Piercamillo Pavesi, Cesare Manotti, Roberto Quintavalla, Tiziana Sinigaglia, Giuliana Guazzaloca, Corrado Pattacini, Stefano Urbinati, Vincenzo Livio Malavasi, Giuseppe Boriani, Claudio Voci, Roberto D'Amico, Nicola Magrini
Issue: January 2019

Oral anticoagulants directly inhibiting Factor IIa o Factor Xa (DOAC) have been marketed in Italy for the prevention of cardiac embolism in patients affected by non-valvular atrial fibrillation (NVAF) since 2013.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.